| |
 See also
|
| |
|
|
|
Press release.
19/01/2010
Cellectis and the French National Institute for Agricultural Research (INRA) sign cooperation agreement
INRA - CELLECTIS
André Choulika, CEO of Cellectis S.A. (Alternext: ALCLS) and Marion Guillou, President of the French National Institute for Agricultural Research (INRA), have signed today a five year cooperation agreement.
|
| |
CELLECTIS and INRA will work together in a number of fields, including cell biology, plant and animal biotechnology, and will investigate the potential of applications of a range of technologies in which Cellectis specializes. These include reverse genetics, homologous recombination and gene targeting. These techniques have a number of applications, notably: inserting many genes of interest at a specified location, developing more efficient genetics, modulating gene expression and replacing alleles. They therefore offer the possibility of technological engineering to enlarge the analysis of gene functions and propose, when possible, innovations in agriculture, environmental sciences, the agrofood sector and green chemistry.
Through this agreement, Cellectis and INRA wish to pool their expertise where possible, to acquire new scientific knowledge and to create technological innovations, along with disseminating these results and knowledge and transferring their technology, particularly to small and medium companies in the agrofood, agriculture and environment sectors.
This non-exclusive partnership will be developed in the field of genome engineering for all living species except humans. It will be monitored by a Steering Committee composed of three representatives from each organization.
About Cellectis S.A.
Cellectis S.A. is a world pioneer in genome engineering and genome surgery. The company focuses on developing and producing custom meganucleases for use in in vivo genome surgery addressing the therapeutic, agrofood, biomanufacturing and research sectors. Worldwide, Cellectis has entered into more than 50 agreements with major players in the pharma, biotech and agrobiotech industries and has over 20 collaborations with academic research groups. To date, Cellectis has raised over €70 million in both equity operations and public financing and is listed on the NYSE-Euronext Alternext market (ticker code: ALCLS). For more information on Cellectis, visit our website: www.cellectis.com.
About INRA
INRA is the French research organization specializing in agriculture, food and the environment, the interactions between these fields and the activities associated with them. It is the European leader in these areas and is ranked second in the world in terms of scientific production. Its activities range from fundamental research to the development of innovative products, software and organizations, as well as expert assessments for public decision-making purposes.
INRA is part of numerous partnerships with socioeconomic leaders : joint research programs with companies and players in the agrodevelopment, joint units with technical institutes, research programs linking public and private sectors in a given area, framework agreement with NGOs. www.inra.fr
|
Disclaimer
This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are based on the current expectations and assumptions of the Company’s management only and involve risk and uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful in implementing its strategies, whether there will be continued growth in the relevant market and demand for the Company’s products, new products or technological developments introduced by competitors, and risks associated with managing growth. Unfavorable developments in connection with these and other risks and uncertainties described, in particular, in the Company’s prospectus prepared in connection with its IPO and on which the French Autorité des marchés financiers (“AMF”) granted its visa n° 07-023 on January 22, 2007, could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.
|
| |
|
Written by :
INRA press service, phone: +33 (0)1 42 75 91 69
Contacts :
For further information, please contact:
For Cellectis:
For INRA: Lise Poulet, + 33 (0)1 42 75 91 68, presse@inra.fr
|
|
|
|
|
